Analyst Price Target is $16.00
▲ +54.74% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Champions Oncology in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 54.74% upside from the last price of $10.34.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Champions Oncology.
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.